This announcement is a separate document:
武田薬品工業：統計学的に優位かつ臨床的に意義ある改善を示すTAK-861の臨床第2b相試験データのSLEEP 2024での発表について
Takeda Pharmaceutical: Regarding the announcement of the clinical phase 2b trial data of TAK-861, which demonstrates statistically significant and clinically meaningful improvement, at SLEEP 2024.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.